Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 417

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 417
---
 the year ended December31, 2024, representing a decrease of $269,163, or 122%, compared to Other expense $219,812 for the year ended December31, 2023. The increase in Other income, net was attributable to favorable exchange rate differences. Interest Expense Interest expense was $45,054, for the year ended December31, 2024 representing a decrease of $74,866, or 62%, compared to expense of $119,920, for the year ended December31, 2023. The decrease was due to less interest due to from notes payable no longer outstanding. Interest on Related Party Loans Interest on related party loans was $104,963, for the year ended December31, 2024 representing an increase of $79,730, or 316%, compared to expense of $25,233, for the year ended December31, 2023. The increase was due to a series of short -termloan agreements with certain existing shareholders of the Company that were forgiven in October 2024. Net Loss As a result of the foregoing, our net loss totaled $1,980,810 for the year ended December31, 2024, representing a decrease of $10,191,219, or 84%, compared to $12,172,029 for the year ended December31, 2023. As a pre -revenueemerging biopharmaceutical company, such losses are expected and aligned with our strategy to achieve long -termvalue through successful product development. Net Loss attributable to common shareholders Our net loss attributable to holders of NLS Common Shares for the year ended December31, 2024 was $4,056,990 and for the year ended December31, 2023 was $12,172,029. The decrease resulted from a reduction in net loss, offset by a deemed dividend totaling $2,076,180 for the incremental value from the modification of various warrants’ exercise price and the fair value of the warrants issued as consideration for executing the September Warrant Amendment and the October Warrant Amendment. Liquidity and Capital Resources Overview During the year December31, 2024, we funded our operations with $5,252,725 from the issuance of NLS Common Shares and preferred shares in private offerings and $173,123 from the exercise of pre -fundedwarrants. As of December31, 2024, we had $1,665,395 in cash and cash equivalents. The table below summarizes our cash flows for